EMA Decides Fast-Track Fate Of Masitinib And Anthrax Antitoxin
The European Medicines Agency is this week deciding whether it will fast track its review of orphan drugs from two companies, one of which has previously tried but failed to get the same product approved for sale in the EU.
You may also be interested in...
Accelerated assessment requests at the European Medicines Agency.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.